|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Institute on Drug Abuse (NIDA) |
|---|---|
| Collaborator: |
Yale University |
| Information provided by: | National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00000194 |
Purpose
The purpose of this study is to study the effects of cycloserine on naloxone-precipitated opiate withdrawal.
| Condition | Intervention | Phase |
|---|---|---|
|
Opioid-Related Disorders |
Drug: Cycloserine |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Double-Blind, Placebo Control |
| Official Title: | Neurobiology of Opioid Dependence: 3 |
Eligibility| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Please contact site for information.
Contacts and Locations| United States, Connecticut | |
| VA Connecticut Healthcare System | |
| New Haven, Connecticut, United States, 06519 | |
| Principal Investigator: | Marc I Rosen, M.D. | VA Connecticut Healthcare System |
More Information
| Study ID Numbers: | NIDA-00191-3, K20-00191-3 |
| Study First Received: | September 20, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00000194 History of Changes |
| Health Authority: | United States: Federal Government |
|
Antimetabolites Cycloserine Anti-Infective Agents Molecular Mechanisms of Pharmacological Action Disorders of Environmental Origin Anti-Infective Agents, Urinary Opioid-Related Disorders Renal Agents |
Pharmacologic Actions Antibiotics, Antitubercular Anti-Bacterial Agents Mental Disorders Therapeutic Uses Substance-Related Disorders Antitubercular Agents |